Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial

Publication | Closed Access

DOI

Citations

References

2016

Year

Lukas Schwentner, Nadia Harbeck, Susanne Singer, Martin Eichler, Brigitte Rack, Helmut Forstbauer, A. Wischnik, Christoph Scholz, Jens Huober, Thomas W. P. Friedl,

The Breast